294 related articles for article (PubMed ID: 29975764)
1. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
3. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
4. Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.
Knight R; Roux P; Vilotitch A; Marcellin F; Rosenthal E; Esterle L; Boué F; Rey D; Piroth L; Dominguez S; Sogni P; Salmon-Ceron D; Spire B; Carrieri MP;
Addiction; 2017 Sep; 112(9):1669-1679. PubMed ID: 28430385
[TBL] [Abstract][Full Text] [Related]
5. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data).
Barré T; Mercié P; Lions C; Miailhes P; Zucman D; Aumaître H; Esterle L; Sogni P; Carrieri P; Salmon-Céron D; Marcellin F;
AIDS Res Ther; 2022 Mar; 19(1):15. PubMed ID: 35292069
[TBL] [Abstract][Full Text] [Related]
6. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
7. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
8. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).
Nordmann S; Vilotitch A; Roux P; Esterle L; Spire B; Marcellin F; Salmon-Ceron D; Dabis F; Chas J; Rey D; Wittkop L; Sogni P; Carrieri P;
J Viral Hepat; 2018 Feb; 25(2):171-179. PubMed ID: 28984055
[TBL] [Abstract][Full Text] [Related]
9. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting Antivirals for HIV/HCV Co-infected Individuals: As Good as it Gets?
Bruno G; Saracino A
Curr HIV Res; 2017; 15(6):422-433. PubMed ID: 29119934
[TBL] [Abstract][Full Text] [Related]
11. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.
Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixco C; Decaestecker J; de Galocsy C; Janssens F; Van Overbeke L; Van Steenkiste C; D'Heygere F; Cool M; Wuyckens K; Nevens F; Robaeys G
J Viral Hepat; 2017 Nov; 24(11):976-981. PubMed ID: 28504854
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
[TBL] [Abstract][Full Text] [Related]
13. Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C.
Fialho R; Pereira M; Harrison N; Rusted J; Whale R
Psychiatry Res; 2017 Jul; 253():150-157. PubMed ID: 28365538
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
[TBL] [Abstract][Full Text] [Related]
15. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
16. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.
Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):351-8. PubMed ID: 24580042
[TBL] [Abstract][Full Text] [Related]
17. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).
Marcellin F; Lions C; Rosenthal E; Roux P; Sogni P; Wittkop L; Protopopescu C; Spire B; Salmon-Ceron D; Dabis F; Carrieri MP;
Drug Alcohol Rev; 2017 Mar; 36(2):227-238. PubMed ID: 27073179
[TBL] [Abstract][Full Text] [Related]
18. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
19. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
20. Effect of antiviral therapy for HCV on lipid levels.
Mauss S; Berger F; Wehmeyer MH; Ingiliz P; Hueppe D; Lutz T; Simon KG; Schewe K; Rockstroh JK; Baumgarten A; Christensen S
Antivir Ther; 2017; 21(1):81-88. PubMed ID: 27685337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]